CAR-T CMC Strategy Under Time Pressure
The challenge
An emerging biotech was developing an autologous CAR-T therapy for oncology. Early scientific data supported continued development and there was strong pressure to progress quickly.
However, the programme was still built on research-grade documentation and did not yet have a single, integrated CMC plan to support progression to clinical supply. Although a scientific interaction had taken place, written feedback and decision records were incomplete, leaving uncertainty around what risks had been addressed and which remained open.
As a result, the programme’s risk profile was not aligned with the pace at which it was expected to move.
3Biotech’s role
3Biotech was engaged to take ownership of the CMC strategy for both the vector and CAR-T product, from preclinical development through to clinical supply. This included:
● Establishing and leading the CMC development plan
● Running a structured gap and risk analysis
● Building an executable manufacturing and analytical strategy
● Selecting and governing CDMOs
● Preparing CMC and quality documentation for regulatory engagement
A tranche-based execution model was put in place, supported by live timelines, risk tracking and defined decision gates.
Key issues identified
A structured CMC risk review highlighted three areas requiring immediate attention.
Safety package uncertainty
Early tissue reactivity findings required further interpretation, including which cell types were affected, whether the signal was functionally relevant and how it would be followed up. In CAR-T development, unresolved off-target or cross-reactivity risks can create significant delays once manufacturing, toxicology and regulatory activities are underway.
An execution-ready development plan
The existing development plan reflected strong science but lacked the operational detail required for an IND- or CTA-enabling programme, including clarity on study sequencing, materials, quality standards and timelines.
A construct change with CMC impact
A new construct incorporating an additional control or safety feature was under consideration. This raised questions around comparability, analytics, manufacturing strategy and IP or freedom-to-operate risk, all of which had implications for both timelines and regulatory strategy.
The CMC strategy
3Biotech put in place an integrated CMC strategy covering product definition, manufacturing, analytics, quality and external partnerships.
A first Target Product Profile was developed to align clinical intent with measurable product characteristics. From this, early critical quality attributes were defined to guide analytical and manufacturing decisions.
Starting materials and critical reagents were defined early, with acceptance criteria, traceability and change control requirements established to protect comparability and process understanding.
At the manufacturing level, plasmid, vector and CAR-T activities were sequenced across engineering and GMP runs. Engineering material was deliberately used to support comparability and toxicology-enabling work, allowing GMP slots to be protected while the construct decision remained open.
Release-enabling analytical methods and documentation were implemented in parallel, providing the basis for clinical release and future comparability arguments. This was particularly important given the inherent patient-to-patient variability in autologous CAR-T manufacture.
CDMOs were selected and governed as an extension of the Sponsor’s quality system, with defined governance structures, action tracking and escalation routes to ensure that manufacturing output remained aligned with the regulatory narrative.